SG193206A1 - Oral formulations of cytidine analogs and methods of use thereof - Google Patents

Oral formulations of cytidine analogs and methods of use thereof

Info

Publication number
SG193206A1
SG193206A1 SG2013061601A SG2013061601A SG193206A1 SG 193206 A1 SG193206 A1 SG 193206A1 SG 2013061601 A SG2013061601 A SG 2013061601A SG 2013061601 A SG2013061601 A SG 2013061601A SG 193206 A1 SG193206 A1 SG 193206A1
Authority
SG
Singapore
Prior art keywords
methods
oral formulations
use
cytidine analogs
cytidine
Prior art date
Application number
SG2013061601A
Inventor
Jeffrey B Etter
Mei Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US5360908P priority Critical
Priority to US20114508P priority
Priority to US15787509P priority
Application filed by Celgene Corp filed Critical Celgene Corp
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG193206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of SG193206A1 publication Critical patent/SG193206A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

104 ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF AbstractThe present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. No Suitable Figure
SG2013061601A 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof SG193206A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US5360908P true 2008-05-15 2008-05-15
US20114508P true 2008-12-05 2008-12-05
US15787509P true 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
SG193206A1 true SG193206A1 (en) 2013-09-30

Family

ID=40941609

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013061601A SG193206A1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Country Status (30)

Country Link
US (5) US8846628B2 (en)
EP (2) EP2299984B1 (en)
JP (3) JP2011520880A (en)
KR (1) KR101633134B1 (en)
CN (3) CN105535008A (en)
AR (1) AR071808A1 (en)
AU (3) AU2009246926B2 (en)
BR (1) BRPI0912717A2 (en)
CA (1) CA2761582A1 (en)
CL (1) CL2013001097A1 (en)
CO (1) CO6300930A2 (en)
CR (1) CR11789A (en)
DK (1) DK2299984T3 (en)
EC (1) ECSP10010665A (en)
ES (1) ES2712506T3 (en)
HR (1) HRP20190100T1 (en)
HU (1) HUE042825T2 (en)
IL (2) IL209307A (en)
LT (1) LT2299984T (en)
MX (2) MX2010012470A (en)
MY (1) MY161593A (en)
NZ (3) NZ602833A (en)
PE (2) PE19712009A1 (en)
PL (1) PL2299984T3 (en)
RU (2) RU2476207C2 (en)
SG (1) SG193206A1 (en)
SI (1) SI2299984T1 (en)
TW (3) TWI618538B (en)
WO (1) WO2009139888A1 (en)
ZA (1) ZA201008229B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
WO2009139888A1 (en) * 2008-05-15 2009-11-19 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
CA2789365A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20140155344A1 (en) * 2010-06-07 2014-06-05 Neil P. Desai Combination therapy methods for treating proliferative diseases
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
MX2013006020A (en) 2011-01-31 2013-10-01 Celgene Corp Pharmaceutical compositions of cytidine analogs and methods of use thereof.
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
KR20140019820A (en) 2011-03-31 2014-02-17 셀진 인터내셔널 에스에이알엘 Systhesis of 5-azacytidine
CA2853949A1 (en) 2011-11-01 2013-05-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
EA028380B1 (en) 2011-11-03 2017-11-30 Миллениум Фармасьютикалз, Инк. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
MX2015000804A (en) * 2012-07-20 2016-03-11 Star Biotechnology Llc Treating ewing's sarcoma and ews-fli1 related disorders.
US20150359810A1 (en) * 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2016029004A1 (en) 2014-08-22 2016-02-25 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20180296583A1 (en) * 2015-10-15 2018-10-18 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (en) 1963-12-22
CH527207A (en) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved A process for the preparation of 1-glycosyl-5-azacytosinen
CH507969A (en) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved A process for the preparation of 1-glycosyl-5-azacytosinen
DE2012888C3 (en) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen, De
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (en) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen, De
DE2508312C2 (en) 1975-02-24 1987-10-29 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De
DE2757365A1 (en) 1977-12-20 1979-06-21 Schering Ag New process for production of nucleosides
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0331437B2 (en) 1985-08-23 1991-05-07 Kirin Amgen Inc
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
CA2267279A1 (en) 1996-10-16 1998-04-23 Devron Averett Monocyclic l-nucleosides, analogs and uses thereof
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CN1361694A (en) 1999-07-16 2002-07-31 天藤制药株式会社 Glycyrrhizin preparations for transmucosal absorption
DE60123384T2 (en) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park "Shell and core" dosage form of the type having a drug release that approaches zero order
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
WO2004041195A2 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (en) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司;孔庆忠 Anti-cancer medicine composition containing antimetabolite
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
PL2301531T3 (en) 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN100500212C (en) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司;孔庆忠 Anti entity tumour medicinal composition
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd Stable highly pure azacitidine and preparation methods therefor
RU2488591C2 (en) 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Azacytidine analogues and use thereof
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
WO2009139888A1 (en) * 2008-05-15 2009-11-19 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
ES2400779T3 (en) 2008-08-06 2013-04-12 Sicor, Inc. Process to prepare an intermediate product of azacitidine
KR101660549B1 (en) 2008-08-08 2016-09-27 시노팜 타이완 리미티드 Process for making azacytosine nucleosides and their derivatives
CA2744158A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Anti-angiogenesis therapy for the treatment of breast cancer
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (en) 2010-03-30 2013-04-11 Chemi Spa Process for the synthesis of azacitidine and decitabine
MX2013006020A (en) 2011-01-31 2013-10-01 Celgene Corp Pharmaceutical compositions of cytidine analogs and methods of use thereof.
KR20140019820A (en) 2011-03-31 2014-02-17 셀진 인터내셔널 에스에이알엘 Systhesis of 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CA2853949A1 (en) 2011-11-01 2013-05-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs

Also Published As

Publication number Publication date
MX363023B (en) 2019-03-05
TW201513869A (en) 2015-04-16
AU2009246926B2 (en) 2014-06-26
ECSP10010665A (en) 2011-01-31
RU2012147739A (en) 2014-05-20
EP2299984B1 (en) 2018-11-28
PE24402014A1 (en) 2015-01-28
AU2015202884A1 (en) 2015-06-18
KR101633134B1 (en) 2016-06-23
CN102099018A (en) 2011-06-15
LT2299984T (en) 2019-03-25
CL2013001097A1 (en) 2013-11-29
TWI522103B (en) 2016-02-21
JP2015110575A (en) 2015-06-18
IL238087A (en) 2019-01-31
NZ589437A (en) 2012-11-30
CO6300930A2 (en) 2011-07-21
AU2015202884B2 (en) 2017-02-23
JP6105547B2 (en) 2017-03-29
NZ602833A (en) 2014-04-30
EP2299984A1 (en) 2011-03-30
AU2009246926A1 (en) 2009-11-19
US20150056280A1 (en) 2015-02-26
US8846628B2 (en) 2014-09-30
ZA201008229B (en) 2012-02-29
PL2299984T3 (en) 2019-07-31
JP2011520880A (en) 2011-07-21
IL209307D0 (en) 2011-01-31
CN105535008A (en) 2016-05-04
HRP20190100T1 (en) 2019-04-05
US20190231803A1 (en) 2019-08-01
US20180153916A1 (en) 2018-06-07
KR20110015629A (en) 2011-02-16
CN103479586A (en) 2014-01-01
AR071808A1 (en) 2010-07-14
TWI618538B (en) 2018-03-21
MX2010012470A (en) 2010-12-02
CN103479586B (en) 2017-03-01
JP6426778B2 (en) 2018-11-21
US20090286752A1 (en) 2009-11-19
RU2476207C2 (en) 2013-02-27
US20150374732A1 (en) 2015-12-31
NZ623495A (en) 2015-08-28
DK2299984T3 (en) 2019-03-04
HUE042825T2 (en) 2019-07-29
IL209307A (en) 2016-02-29
TW201006478A (en) 2010-02-16
TW201729817A (en) 2017-09-01
BRPI0912717A2 (en) 2014-12-23
WO2009139888A1 (en) 2009-11-19
EP2695609A1 (en) 2014-02-12
SI2299984T1 (en) 2019-04-30
AU2013202665B2 (en) 2015-06-25
AU2013202665A1 (en) 2013-05-02
ES2712506T3 (en) 2019-05-13
RU2010151428A (en) 2012-06-20
CN102099018B (en) 2016-01-13
JP2017137326A (en) 2017-08-10
PE19712009A1 (en) 2010-01-15
US10220050B2 (en) 2019-03-05
CA2761582A1 (en) 2009-11-19
CR11789A (en) 2011-02-21
MY161593A (en) 2017-04-28

Similar Documents

Publication Publication Date Title
AU2017204772B2 (en) Compositions and their uses directed to huntingtin
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
TW201040185A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation and uses thereof
MX352480B (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate.
MXPA06012059A (en) New pharmaceutical compositions for the treatment of sexual disorders ii.
EA201500430A1 (en) Compounds of bononate air and its pharmaceutical compositions
IL197393A (en) Pyridin-4-yl derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for treatment of diseases associated with the immune system
TW200817355A (en) Benzimidazolyl compounds
WO2006099169A3 (en) Novel liposome compositions
TW200637614A (en) Bendamustine pharmaceutical compositions
IL173909A (en) Use of modified cyclosporins in the preparation of pharmaceutical compositions for the treatment of hcv disorders
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
ZA200705281B (en) Pyrido(3,2D)pyrimidines and pharmaceutical compositions useful for medical treatment
BRPI0908292A2 (en) "methods and compositions for oral administration of exenatide"
AU2007257423A8 (en) Purine analogs
NZ589307A (en) Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
MXPA06001876A (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use.
CA2640451A1 (en) Medicine for transnasal administration
IL166202A (en) Azolidinone-vinyl benzene derivatives, their preparation and their use in the preparation of pharmaceutical compositions for the treatment of diseases
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
NZ585720A (en) Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies